#ExistInterpDataSet>
| Interpretive Data: |
#ExistInterpData>Refer to report.
Refer to Statement B under Testing Information at http://www.aruplab.com.
*ExistInterpData>
|
*ExistInterpDataSet>
#ExistNote>
| Note: |
CBFB (core binding factor β-chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts are detected in approximately 10% of de novo acute myelogenous leukemias (AML). One half of these cases belong to AML subtype M4 with abnormal eosinophils (AML-M4Eo). The fusion results from a pericentric inversion on chromosome 16 inv(16)(p13q22) or rarely from the translocation t(16;16)(p13;q22). Based on the breakpoints in the CBFB and MYH11 genes, greater than 95% of analyzed inv(16) cases belong to three types: A (88%), D (5%), and E (5%).
|
*ExistNote>
#ExistCPT>
| CPT Code(s): |
83891 Isolation; 83902 Reverse transcription; 83898 x5 Amplification; 83894 x3 Gel separation; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
|
*ExistCPT>
#ExistCrossReferences>
Cross References: |
inv(16) (CBFB-MYH1, inv(16) by RT-PCR)
|
*ExistCrossReferences>